Despite progress in therapies like immunotherapies, multiple myeloma (MM), an incurable blood cancer, often resists treatment, calling for new approaches. Natural killer (NK) cells, crucial in our immune system, target cancerous or infected cells. Lab-expanded NK cells from donors can be safely infused in patients, with minimal risk to normal tissues. Our prior studies revealed MM cells evading attack and weakly activating NK cells. I will test patient-derived MM cells, diverse in biology and disease stage, to understand resistance and find responsive patients. To boost effectiveness, we aim to modify NK cells for MM cell recognition. Engineered NK cells will be tested on resistant MM cells. I will also explore resistance mediated by non-cancerous cells around MM, that may affect NK cell efficacy, to identify new therapeutic targets, ultimately improving NK cell therapy. These studies may guide future trials, enhancing NK cell-based therapies for better MM patient outcomes.

2024

2028